Spectral AI, Inc. services

SpectralAI's DeepView technology offers an advanced clinical decision support system specifically designed for the management of Diabetic Foot Ulcers (DFUs). Unlike current diagnostic methods such as trans-cutaneous oxygen measurement and doppler ultrasounds, which fail to predict wound healing, DeepView utilizes AI to provide a more precise assessment. With an 86% accuracy rate in predicting whether a DFU will close by 50% within four weeks, the technology aids in making informed, timely decisions for patient treatment. This not only accelerates therapy adjustments but also decreases overall clinician visits, ultimately enhancing patient satisfaction. The technology aims to address a significant healthcare challenge, as diabetic foot disease incurs annual costs of 9 to 13 billion dollars in the U.S alone. By leveraging DeepView, clinicians gain a tool that significantly improves their ability to manage the complexities and comorbidities associated with DFUs.

DeepView’s Day One prediction eliminates subjective biases and provides a more accurate evaluation of wound healing.